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We document an increase in the number of multidrug-
resistant Salmonella enterica serovar Paratyphi B dT
+ iden-
tified in Canada. Most of these strains harbor Salmonella
genomic island 1 (SGI1). Further studies are needed to
determine factors contributing to the observed emergence
of this multidrug-resistant strain.
S
almonella genomic island 1 (SGI1) was first character-
ized in Salmonella enterica serovar Typhimurium
definitive phage type 104 (DT104). It consists of a 43-kb
DNAsegment harboring genes responsible for the pentare-
sistance phenotype ampicillin, chloramphenicol, strepto-
mycin, sulfonamide, and tetracycline (ACSSuT) and is
inserted into the chromosome at the end of the thdF gene
(1). Complete nucleotide sequence of this region revealed
44 open reading frames, of which some displayed homol-
ogy to genes associated with plasmid transfer, which sug-
gests SGI1 may be at least partially plasmidic in origin (2).
The SGI1 is associated with the multidrug-resistant DT104
clone that has disseminated worldwide (3). Recently, a
number of reports have described SGI1 and variants in
other Salmonella serovars, including S. Agona, S. Albany,
and S. Paratyphi B dT+ (2,4–6). The worldwide dissemina-
tion of the DT104 clone has led some investigators to sug-
gest SGI1 contains genes that may provide a selective
advantage to the organism (2,4). We document the rapid
increase of S. Paratyphi B dT+ isolates harboring SGI1 in
Canada and provide further evidence to support that other
unknown genetic factors may contribute to the rapid dis-
semination of multidrug-resistant strains of Salmonella
serotypes globally.
The Study
This report is a result of a collaborative effort between
the National Microbiology Laboratory (NML), Health
Canada, and the Provincial Public Health Laboratories
(PPHLs) in Canada. The PPHLs represent every province
in Canada and also include the Yukon and North West
Territories. All S. Paratyphi B dT+ identified at the PPHLs
were forwarded to the NMLfor additional characterization.
Between 1998 and 2002, 252 S. Paratyphi B dT+ strains
were submitted to the NML, of which 246 were from a
human source. Distribution of the strains over time is
shown in Figure 1. Incidence of S. Paratyphi B dT+ has
generally increased since 1998; the spike in S. Paratyphi B
dT+ in the third and fourth quarters of 1999 can be attrib-
uted to an outbreak in British Columbia, Alberta, and
Saskatchewan caused by contaminated alfalfa sprouts (7).
In addition to this large outbreak, additional outbreaks
were reported between 1998 and 2002; however, each out-
break was small, and most involved fewer than six persons. 
Antimicrobial susceptibility testing was performed on
all strains by using the disk-diffusion method as described
by the National Committee for Clinical Laboratory
Standards (8). Susceptibilities were determined for ampi-
cillin (A), chloramphenicol (C), ciprofloxacin (Cp), strep-
tomycin (S), sulfamethoxazole (Su), tetracycline (T), and
trimethoprim (Tm). Of the 237 strains examined for sus-
ceptibility, 123 (52%) were susceptible to all antimicrobial
agents tested. Sixty-seven strains (28%) displayed the
pentaresistance phenotype (ACSSuT), and the second
most prevalent resistance profile was Su (n = 41, 17%).
Single strains displayed the phenotypes A, T, CSSu,
ASuTm, ASSu, and ACSuTTm. Asignificant increase was
observed in ACSSuT strains over the time period from
1998 to 2002 (p < 0.001). Rates for the years are as fol-
lows: 1998, n = 2 (2%); 1999, n = 4 (18%); 2000, n = 2
(10.5%); 2001, n = 23 (39%); and 2002, n = 36 (58%). No
large outbreaks were reported during this time period. To
determine if the pentaresistance phenotype was caused by
SGI1, polymerase chain reaction (PCR) was used to detect
integrons and the left (thdF-S001) and right (S044-yidY)
junctions of SGI1 as previously described (2). Of the 67
strains identified with the ACSSuT phenotype, 63 con-
tained 1.0-kb and 1.2-kb integrons and left and right junc-
tions of SGI1, which suggests that these strains contained
SGI1 inserted into the same location on the chromosome
as was described for DT104 (1). One strain with the
ACSSuT phenotype contained 1.0-kb and 1.2-kb integrons
and gave a PCR product for the left junction amplification
reaction but not the right junction, which suggests that a
portion of SGI1 downstream of the integrons was missing.
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characteristic size products for integron (0.7 kb, n = 2; 2.0
kb, n = 1), and all were negative for the junction PCR,
which suggests that these strains most likely harbored
other resistance genes giving the ACSSuT phenotype.
Only four strains with the ACSSuT phenotype were iden-
tified from a nonhuman source (one poultry, three environ-
mental). Although the three environmental isolates
contained SGI1, the ACSSuT strain isolated from poultry
did not; instead, it contained a 2-kb integron. Of the human
isolates for which source was reported for the ACSSuT
strains (n = 53), all were isolated from stool, with the
exception of three that were isolated from blood. To ensure
the SGI1 was intact, a selected number of isolates were
subjected to additional PCR with primers representing all
regions of the 44-kb SGI1 element (Table). PCR condi-
tions used were previously described (2). DNA from all of
these strains gave positive reactions for all primer sets
described, which suggests SGI1 was intact in these strains. 
S. Paratyphi B dT+ recovered from 2000 to 2002 were
subtyped by using pulsed-field gel electrophoresis (PFGE)
after DNA extraction and digestion with BlnI according to
the standardized Salmonella protocol (9). PFGE-generated
DNA profiles were entered into the BioNumerics software
program version 3.0 (Applied Maths, St. Martens-Latem,
Belgium) for analysis. Cluster analysis was performed by
the unweighted pair-group method with arithmetic aver-
ages, and DNA relatedness was calculated on the basis of
the Dice coefficient. In addition, all PFGE patterns were
visually compared and assigned a number or letter identifi-
cation (10). Adendrogram depicting the S. Paratyphi B dT+
BlnI macrorestriction patterns is shown in Figure 2. Of the
139 strains available to subtype (total = 142), visual com-
parison of the fingerprints revealed a total of 63 unique fin-
gerprint patterns that grouped into 24 clusters. Analysis of
the dendrogram revealed that all but three strains with the
ACSSuT phenotype were grouped into three closely relat-
ed clusters named clusters 1 to 3 (Figure 2). The three
strains that did not cluster with the other ACSSuT strains
did not harbor SGI1 as described above.
Cluster 1 contained 32 strains that represented 10 sub-
types. Cluster 2 contained 17 strains that represented 7
subtypes, all of which showed <7 band differences
between strains from cluster 1. Cluster 3 contained 15
strains that represented 6 subtypes, all of which showed
fewer than seven band differences between subtypes in
cluster 2, but had more than seven band differences
between the cluster 1 fingerprints. In addition, six other
strains identified before 2000 were subtyped. Five were
other ACSSuT identified in 1998 (n = 1) and 1999 (n = 4),
and all were identified in cluster 2. In addition, one S.
Paratyphi B dT+ recently shown to harbor SGI1 that was
isolated in Singapore from a fish was grouped into cluster
3 (4). The Canadian isolates in clusters 1 to 3 have been
identified from multiple provinces, including British
Columbia, Alberta, Manitoba, Ontario, and Québec, repre-
senting western and central regions of Canada.
Conclusions
The emergence of multidrug-resistant S. Paratyphi B
dT+ was documented recently in the Netherlands and
Scotland (11,12). Some isolates had the ACSSuT suscepti-
bility pattern and did not harbor any plasmids, which sug-
gests the resistance is of chromosomal origin (12).
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Table. PCR primer to detect various regions of SGI1 
Set  Primer  Primer sequence (5′ to 3′)  Coordinates
a  Product size (bp) 
St1  U9-L1 
P1-R1 
TACTACAAGCAGATAACGCC 
TAGAAACGACAAAGCGCGTG 
2771–2790 
3660–3679 
909 
St3  P134-L1 
P134-R2 
AATCGACACGCGCTGTATTG 
CTTCCCATAATGCCGCAATG 
16350–16369 
17287–17306 
957 
St4  P134-L1 
P134-R1 
TGACCCAATTCCAAAGCCAC 
GTGTTTGGGCAAGATCCCAG 
16784–16803 
17820–17839 
1490 
St5  St2-GP21 
St2-GP6 
ATAACGGCAGGTTCCGGTTC 
CGATGAAGCGCACAAATTTG 
20173–20192 
21089–21108 
936 
St6  St2-GP24 
St2-GP28 
TCAAGATTCCTATCTGCAGG 
AGAGTTACTAGACCAAGCGC 
24363–24382 
25182–25201 
838 
aCoordinates from accession no. AF261825. 
Figure 1. Total number of Salmonella enterica serovar Paratyphi B
dT+ identified in Canada (gray bars) and the number of multidrug-
resistant S. Paratyphi B dT+ identified over the same period (black
bars), by quarter. However, in neither study was the presence of SGI1 or
other resistance genes examined. We demonstrate the rapid
emergence of multidrug-resistant S. Paratyphi B dT+ in
Canada. The increase is due to three clusters, all of which
contain the multidrug-resistant genomic island SGI1. That
three closely related clonal groups were present suggests
SGI1 may have inserted into the genome of S. Paratyphi B
dT+ in three separate events, as shown by clusters 1, 2, and
3, or the insertion may have occurred once, with strains
diverging over time. We also identified three strains with
the ACSSuT phenotype that did not contain SGI1
sequences, which emphasizes the need to monitor geno-
typic resistance factors and not just phenotypic resistance
traits to understand the dissemination of antimicrobial
resistance.
The emergence of multidrug-resistant enteric
pathogens is a concern because of the lack of suitable
antimicrobial agents available to treat invasive infections.
One organism that emerged in the 1990s is multidrug-
resistant S. Typhimurium DT104, which harbors SGI1 (3).
Along with the multidrug-resistant phenotype, reports sug-
gest the strain may be more virulent than other salmonel-
lae (13,14). However, in vitro studies have not shown any
increase in invasiveness or survival in mammalian cells
(15,16). Whether multidrug-resistant DT104 is more viru-
lent remains to be determined, the underlying question
remains: why has this clone of DT104 emerged as a major
pathogen? Selective pressure, resulting from the wide-
spread use of antimicrobial drugs in animals for growth
promotion or prophylaxis, may have played a role in dis-
seminating this organism. However, this factor may not
completely account for its prevalence, because other mul-
tidrug-resistant strains of DT104 have emerged but have
not disseminated internationally. Other factors may con-
tribute to the international dissemination of this clone. For
example, additional determinants in SGI1 may contribute
to the fitness or virulence of Salmonella strains harboring
it. In the present study, three closely related clusters of S.
Paratyphi B dT+ carrying SGI1 have emerged in Canada
and make up 46% (64 of 139) of all strains identified in
2001 and 2002. Furthermore, three additional S. Paratyphi
B dT+ strains with the ACSSuT phenotype were identified
that do not harbor SGI1 and do not appear to be rapidly
increasing in Canada. In this hypothesis, SGI1 may predict
the next emerging Salmonella serotype. Other factors, such
as processing food products and the structure of the food
distribution system, could play a role in disseminating
these organisms. We continue to monitor this pathogen and
are designing studies to improve understanding of the epi-
demiology of S. Paratyphi B dT+ in Canada. We suggest all
strains of Salmonella with the ACSSuT phenotype be
examined for SGI1.
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